Sep 17, 2020

Cardiac Resynchronization Therapy (CRT)

Information about devices used for Cardiac Resynchronization Therapy.

The following media kits are made available to provide reporters with background information on the range of Medtronic therapies and the conditions they treat.

	May 10, 2019 New Studies Highlight Underuse of Implantable Cardiac Devices Treatment Disparities Prevent Indicated Patients from Receiving Evidence-Recommended Life-Saving Devices DUBLIN and SAN FRANCISCO - May 10, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs)...
	May 1, 2019 Medtronic Receives FDA Approval for World's First Quadripolar Active Fixation Left Heart Lead Attain Stability(TM) Quad MRI SureScan(TM) Lead Designed for Precise Placement and Stability DUBLIN - May 1, 2019 - Medtronic plc (NYSE:MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead....
	May 15, 2018 New Analysis Shows Medtronic Cardiac Resynchronization Therapy Feature Associated with Improved Patient Survival Real-World Data on AdaptivCRT(TM) Algorithm Presented at Heart Rhythm 2018 DUBLIN - May 15, 2018 - Medtronic plc (NYSE: MDT) announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated with improved patient survival. The data were recently...
	Mar 20, 2018 New Analyses Confirm Patients with Medtronic CRT Devices Experience Less Atrial Fibrillation, Are More Active Positive Data on Exclusive AdaptivCRT(TM) Feature Unveiled at EHRA Scientific Sessions 2018 DUBLIN and BARCELONA, Spain - March 20, 2018 - Two real-world analyses featuring the Medtronic plc (NYSE: MDT) AdaptivCRT(TM) algorithm reinforce that its use is linked to a reduction in atrial...
	Jun 20, 2017 New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity DUBLIN and VIENNA - June 20, 2017 - Medtronic plc (NSYE: MDT) today announced new data showing that use of its cardiac resynchronization therapy (CRT) devices - with its proprietary AdaptivCRT(TM)...
	May 15, 2017 Data Reinforce Benefits of Medtronic Cardiac Resynchronization Therapy Technologies in 'Real-World' Setting EffectivCRT(TM)and AdaptivCRT(TM) Exclusives Featured in Heart Rhythm 2017 Presentations DUBLIN - May 15, 2017 - Medtronic plc (NYSE: MDT) today announced new data supporting the clinical performance of the company's exclusive EffectivCRT(TM) Diagnostic and AdaptivCRT(TM) algorithm in...
	May 10, 2017 Medtronic First to Receive FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers Portfolio of Next Generation Heart Failure Devices Offers Effective Pacing and Access to the Most Advanced Diagnostic Imaging Procedures DUBLIN - May 10, 2017 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps)...
	Feb 27, 2017 New Analysis of Reverse Trial Shows Medtronic CRT Devices Cost-Effective, While Helping Patients with Mild Heart Failure Live Longer JACC: HF Study Showcases Economic Value of Earlier Patient Access to Cardiac Resynchronization Therapy DUBLIN - Feb. 27, 2017 - Medtronic plc (NYSE:MDT) today announced an economic analysis of five-year data showing that patients with mild heart failure who get cardiac resynchronization therapy...
	Nov 14, 2016 Medtronic Receives FDA Approval for Claria MRI(TM) Quad Cardiac Resynchronization Therapy Defibrillator First CRT-D in U.S. to Help Improve Therapy Delivery in Heart Failure Patients Using Effective Pacing DUBLIN - Nov. 14, 2016 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI(TM) Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D)...
	Oct 13, 2016 Medtronic Cardiac Devices Gain FDA Approval to Enable Patient Access to the Most Advanced Diagnostic Imaging Patients with SureScan® Pacemakers, ICDs and CRT-Ds Now Can Receive 3 Tesla MRI Scans DUBLIN - Oct. 13, 2016 - Medtronic plc (NYSE:MDT) is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac rhythm and heart failure devices and...
	Sep 19, 2016 Analysis Shows Positive Association Between Cardiac Resynchronization Therapy and Patients' Increased Adherence to Heart Failure Medication Regimens DUBLIN and ORLANDO, Fla. - Sept. 19, 2016 - Medtronic plc (NYSE:MDT) announced the results of an analysis that reveals patients increasingly adhere to heart failure medications after they receive...
	Feb 5, 2016 Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators Amplia MRI(TM) and Compia MRI(TM) CRT-Ds, Approved for Patients with Heart Failure, Can Safely Undergo Full Body MRI Scans DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI)...
	Dec 11, 2014 Medtronic Receives FDA Approval and Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads Additional Attain Performa® Quadripolar Leads Provide Physicians with More Options to Optimize Delivery of Proven Heart Failure Treatment MINNEAPOLIS - Dec. 11, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa® left...
	Nov 16, 2014 Medtronic Studies Show Cardiac Resynchronization Therapy Extends Life, Reduces Hospital Readmissions Data Demonstrate Clinical and Economic Value of Underutilized Treatment for Heart Failure Patients at American Heart Association's Scientific Sessions 2014 MINNEAPOLIS and CHICAGO - Nov. 16, 2014 - Medtronic, Inc. (NYSE: MDT) today announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices for...
	Aug 27, 2014 Medtronic Announces First Implants in Largest-Ever, Global Trial of Cardiac Resynchronization Therapy Post-Market Clinical Trial Will Assess Superiority of the AdaptivCRT® Feature Compared to Standard CRT MINNEAPOLIS - Aug. 27, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first implants in a clinical trial that will compare patient and healthcare system outcomes - including patient...
	Apr 10, 2014 Medtronic CRT Devices Now Approved to Treat Patients with AV Block and Reduced Heart Function Landmark BLOCK HF Trial Demonstrates Clinical Benefits of Biventricular Pacing in New Patient Population MINNEAPOLIS - April 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with...
	Apr 10, 2012 Medtronic Receives FDA Approval to Treat Mildly Symptomatic Heart Failure Patients Through Expanded Indication for CRT-D Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population MINNEAPOLIS--(BUSINESS WIRE)--Apr. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac...
	May 11, 2012 New Data from Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 11, 2012-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in...
	May 18, 2015 Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment for Heart Failure Patients Positive Results from Two Studies Featured at Heart Rhythm Society 36th Annual Scientific Sessions DUBLIN and BOSTON - MAY 18, 2015 -Medtronic plc (NYSE: MDT) today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more...
	Aug 27, 2012 Five-Year Analysis of Pivotal REVERSE Trial Demonstrates Long-Term Clinical Benefits of Medtronic CRT-D Therapy in Mild Heart Failure Patients Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic...
	Jun 18, 2014 Study Shows CRT-D Devices With Medtronic AdaptivCRT™ Associated With Reduction Of Costs Of Atrial Fibrillation Study Supplements Earlier Data Showing Reduction in Hospital Readmissions for Heart Failure Patients with AdaptivCRT Technology MINNEAPOLIS, USA and NICE, FRANCE – June 18, 2014 – New data from the Medtronic, Inc. (NYSE: MDT) Adaptive CRT trial show a 61 percent (p=0.01) lower risk of atrial fibrillation (AF)-related...
	Aug 7, 2014 Medtronic Receives FDA Approval for Attain Performa® Quadripolar Lead and Viva® Quad CRT-Ds in United States New System Helps Physicians Deliver Cardiac Resynchronization Therapy Optimally and Efficiently to Heart Failure Patients MINNEAPOLIS - Aug. 7, 2014 - Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa® Model 4298 quadripolar...